ORIGINAL ARTICLESHumanised monoclonal antibody therapy for rheumatoid arthritis
References (23)
- et al.
A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants
J Immunol Methods
(1990) - et al.
Removal of T cells from bone marrow for transplantation: a monoclonal anti-lymphocyte antibody that fixes human complement
Blood
(1983) - et al.
Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis
Lancet
(1991) - et al.
Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody
Lancet
(1991) Manipulation of T-cell responses with monoclonal antibodies
Annu Rev Immunol
(1989)- et al.
Immunotherapy of rheumatoid arthritis
Ann Rheumatol
(1992) The antiglobulin response to therapeutic antibodies
Semin Immunol
(1990)- et al.
Reshaping human antibodies for therapy
Nature
(1988) - et al.
Humanisation of monoclonal antibodies for therapy
Semin Immunol
(1990) - et al.
The CAMPATH-1 antigen (CDw52)
Tissue Antigens
(1990)
Genes associated with rheumatoid arthritis and mild inflammatory arthritis. II. Association of HLA with complement C3 and immunoglobulin Gm allotypes
Ann Rheum Dis
Cited by (307)
Immune monitoring of patients treated with anti-CD20 therapeutic monoclonals for autoimmune disorders
2023, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2Modulating T-cell activation with antisense oligonucleotides targeting lymphocyte cytosolic protein 2
2022, Journal of AutoimmunityCitation Excerpt :In these patients, modulating T-cell activation represents a promising therapeutic objective, but so far, a limited number of such drugs have been approved. T-cell depletion using monoclonal antibodies was pioneered by the anti-CD52 monoclonal CAMPATH-1H [32], which gave some clinical efficacy in RA patients despite side effects due to long term T-cell depletion [33]. Today indirect T-cell targeting is commonly used in the form of CTLA4-Ig (Abatacept), a soluble receptor binding to co-stimulatory molecules on APCs and is used in many disease settings, including RA [8].
Alemtuzumab in renal transplantation. Reviews of literature and usage in the United Kingdom
2022, Transplantation ReviewsTolerance-inducing medicines in autoimmunity: rheumatology and beyond
2020, The Lancet RheumatologyCitation Excerpt :Following renal transplantation, the addition of a rodent IgM CD52 mAb (Campath-1M) to standard immunosuppression reduced acute cellular rejection but increased serious infection risk.37 Studies of alemtuzumab (humanised Campath-1H) in rheumatoid arthritis suggested therapeutic benefit for some participants, often lasting for 6 months or longer after a brief course of therapy.38,39 These trials were curtailed largely because of chronic therapy-induced lymphopenia.
Immunotoxicology of Biopharmaceutics
2018, Comprehensive Toxicology: Third Edition